Why does the Theranos story still matter in 2026? Because a new documentary, You Can See Everything, has put Elizabeth Holmes back in front of cameras, and because the failure the film circles — a diagnostics company whose tests never worked — remains the clearest case study in what happens when medical claims outrun evidence. Per MIT Technology Review, the film is an intimate portrayal of Holmes, her partner Billy Evans, and their two young children, filmed beginning about a month before she started serving her sentence in May 2023.
The foundations of the story are simple to state. Holmes dropped out of Stanford in 2003 at 19 to run Theranos, a diagnostics company she founded. She claimed the company could run more than 100 diagnostic tests on a few drops of blood, raised hundreds of millions of dollars, and saw the company valued at $9 billion in 2014, per the same account. Forbes named her the youngest self-made female billionaire, worth $4.5 billion at 30. None of the testing claims survived contact with independent scrutiny.
For anyone entering the biotech field, the case is required reading — not for the drama, but for the specific, checkable missteps that let it happen. We covered a connected angle in Where Lab Automation Actually Stands in Biotech Right Now.
What was Theranos actually claiming?
Theranos pitched a familiar dream in diagnostics: comprehensive testing from a finger-prick volume of blood instead of standard venous draws. The stated capability was more than 100 diagnostic tests on just a few drops of blood. That claim is what investors bought, and what the company's $9 billion valuation in 2014 rested on, according to MIT Technology Review's recap of the case.
The gap between that claim and reality surfaced in 2015, when an investigation by the Wall Street Journal raised concerns from former employees that the tests did not work. Former staff also said the company's device had not been tested properly, and that blood samples were analyzed on machines from other companies instead. MIT Technology Review named Theranos one of the biggest technology failures of 2015.
How did the fraud unravel, step by step?
The collapse followed a documented sequence, and each step is worth knowing as a pattern:
- 2015: The Wall Street Journal investigation publishes concerns from former employees about test accuracy and improper device validation, with samples reportedly run on competitors' machines.
- 2016: Forbes revises Holmes's net worth to $0. A government report that year found the company's lab was struggling with basic procedures and gave patients results even when staff knew they could be wrong.
- 2018: Theranos, Holmes, and former company president Ramesh Balwani are charged with "massive fraud."
- 2022: Holmes is sentenced to a little over 11 years in prison for defrauding investors.
- May 2023: She begins serving her sentence.
That timeline, drawn from MIT Technology Review's summary, shows how long the distance can be between a public claim and its reckoning — nearly a decade from founding claims to sentencing.
Why did so many smart people believe it?
This is the question the documentary raises most sharply, and the answer matters for anyone covering or funding science. Journalists who profiled Holmes later owned their misjudgments. "I blew it," wrote Fortune's Roger Parloff in 2015, a year after profiling Holmes. "I'm pretty sure she lied to me," STAT's Matthew Herper wrote recently, having interviewed her in 2015. Even Tyler Shultz, the former employee turned whistleblower who knew the product did not work, said in 2022 that he could "have a five-minute conversation with her and walk away feeling like my work was changing the world."
Holmes is, by the account of people who spent time with her, an effective manipulator. The film's reviewer describes watching her plant seeds of doubt in the mind of filmmaker Nathan Fielder, who appears as a central character, and feeling herself half-convinced in the cinema seat. Persuasion is not evidence. That distinction is the foundation every newcomer to health technology needs to internalize.
What does peer review have to do with it?
One of the earliest red flags in the Theranos case was the absence of published, peer-reviewed data. Much of the company's work was classified as a "trade secret." Peer review is the process by which scientists publish work in journals and have it evaluated by often anonymous experts who provide feedback, flag questionable conclusions, and ask for clarification. It is meant to add rigor. A company that withholds data from that process is asking to be trusted on assertion alone.
Peer review is not a guarantee. Scientists sometimes exaggerate results, inflate their importance, or manipulate data to serve a hypothesis, and not every infraction is caught. Findings that other labs could never replicate have collapsed under real evidence. Many papers end up corrected; some are withdrawn — 10,000 research papers were retracted in 2023, per MIT Technology Review. The system is a filter, not a seal of truth.
How has scientific publishing changed since Theranos?
Verification has arguably gotten harder, not easier. Many scientists now post work on preprint servers such as arXiv, medRxiv, and bioRxiv before journal submission, and those outlets bypass peer review. So do company press releases, social media posts, and many conference presentations. A large share of science coverage also grows out of conversations and interviews rather than papers.
The practical discipline for readers is to ask, for any new claim: has this been reviewed by independent experts, and has anyone outside the company reproduced it? Coverage of diagnostics launches — from point-of-care molecular testing to sequencing chemistry improvements — should be read the same way. The Theranos story is the standing reminder of why that question exists. For related coverage, see What Recent Point-of-Care Molecular Diagnostics Launches Mean for Decentralized Testing.
What does the new documentary add?
The film, from filmmakers Nathan Fielder, Lance Oppenheim, and colleagues, documents Holmes and Billy Evans at home with their two young children in the month before her imprisonment began. The reviewer describes extreme close-ups and an atmosphere in which the subjects seem to be figuring each other out. Holmes invited the cameras in, in an apparent bid to reframe the narrative and present herself as an honest person with an unusual mind.
Whether that reframing works is an open question the reviewer declines to answer, and spoilers are not given here either. What the film's reception confirms is the durable pull of the story: an appealing narrative can still outrun the evidence, even when the evidence is a matter of public record.
What remains settled is the record: the tests did not work as claimed, patients received results the lab knew could be wrong, and the fraud led to criminal charges and an 11-year sentence. What remains unsettled is how reliably the industry, the press, and the public will spot the next Theranos before the money and the patients are already committed. The foundations of that vigilance — published data, independent replication, skeptical questions about any "trade secret" — are the real lesson the documentary reopens.
